First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban
Tokyo, Japan and Edison, N.J. – February 3, 2010 – Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral...